» Articles » PMID: 34621033

Differential Impact of Antihypertensive Drugs on Cardiovascular Remodeling: a Review of Findings and Perspectives for HFpEF Prevention

Overview
Journal Hypertens Res
Date 2021 Oct 8
PMID 34621033
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure (HF) is an important health problem worldwide whose stages have traditionally been classified from A to D. In addition, HF can be categorized as that with preserved ejection fraction (HFpEF) and that with reduced ejection fraction (HFrEF). Hypertension and arterial stiffness in stage A HF are major drivers of the progression to left ventricular hypertrophy (LVH), a criterion of stage B HF. Although the pathogenesis of HFpEF is heterogeneous, affected patients tend to be older than HFrEF patients and have a greater prevalence of hypertension, which is closely associated with arterial stiffness and LVH. Thus, to treat HFpEF, the optimal intervention for improving prognosis is an aggressive approach to early-stage, i.e., Stage A and B, HF. This paper reviews the findings on arterial stiffness and LVH using conventional antihypertensive drugs such as angiotensin receptor II blockers (ARBs) and a new drug class for HF, ARB/neprilysin inhibitor (ARNi). Previous studies have suggested that the combination of an ARB with an L-T-type calcium channel blocker might be recommended for the improvement of arterial stiffness and regression of LVH. More recent research has shown that ARNi also improves central BP, which leads to a reduced afterload and a significant reduction in LVH. For optimal treatment of HFpEF, drug therapy should directly address arterial stiffness as well as hypertension.

Citing Articles

2023 update and perspectives.

Mogi M, Tanaka A, Node K, Tomitani N, Hoshide S, Narita K Hypertens Res. 2023; 47(1):6-32.

PMID: 37710033 DOI: 10.1038/s41440-023-01398-5.


Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension.

Nagai M, Dote K, Forster C Hypertens Res. 2023; 46(7):1727-1737.

PMID: 37045971 DOI: 10.1038/s41440-023-01272-4.


Update on Hypertension Research in 2021.

Mogi M, Maruhashi T, Higashi Y, Masuda T, Nagata D, Nagai M Hypertens Res. 2022; 45(8):1276-1297.

PMID: 35790879 PMC: 9255494. DOI: 10.1038/s41440-022-00967-4.


Seven-action approaches for the management of hypertension in Asia - The HOPE Asia network.

Kario K, Chia Y, Siddique S, Turana Y, Li Y, Chen C J Clin Hypertens (Greenwich). 2022; 24(3):213-223.

PMID: 35172037 PMC: 8925006. DOI: 10.1111/jch.14440.

References
1.
Yasuda S, Miyamoto Y, Ogawa H . Current Status of Cardiovascular Medicine in the Aging Society of Japan. Circulation. 2018; 138(10):965-967. DOI: 10.1161/CIRCULATIONAHA.118.035858. View

2.
Okura Y, Ramadan M, Ohno Y, Mitsuma W, Tanaka K, Ito M . Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J. 2008; 72(3):489-91. DOI: 10.1253/circj.72.489. View

3.
Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Colvin M . 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society.... Circulation. 2017; 136(6):e137-e161. DOI: 10.1161/CIR.0000000000000509. View

4.
Tsutsui H, Isobe M, Ito H, Okumura K, Ono M, Kitakaze M . JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. Circ J. 2019; 83(10):2084-2184. DOI: 10.1253/circj.CJ-19-0342. View

5.
Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View